July 2026
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of semaglutide on cardiovascular events and body weight in adults with type 2 diabetes, finding significant reductions in several cardiovascular outcomes.
Outcomes
Body weightCardiovascular deathComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)+5 more
Added to Dediabetes Jul 12, 2026RCTs
The FLOW trial investigated the effects of semaglutide on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease, revealing significant reductions in cardiovascular death, myocardial infarction, and stroke.
Outcomes
All-cause mortalityComposite of CV death, non-fatal myocardial infarction, or non-fatal stroke
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of semaglutide combined with insulin therapy on glycemic control and renal function in elderly patients with type 2 diabetes, finding significant improvements in several metabolic parameters.
Interventions
Insulin therapy
Outcomes
24-Hour Urinary Protein (24hUpr)Adverse events incidenceEndothelin-1 (ET-1)+9 more
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of SGLT2 inhibitors on cardiovascular and kidney outcomes across different levels of albuminuria. It found significant reductions in albuminuria and various adverse outcomes compared to placebo.
Interventions
SGLT2 inhibitors
Outcomes
AlbuminuriaAll-cause mortalityAtherothrombotic events+3 more
Added to Dediabetes Jul 12, 2026RCTs
This study compared the real-world effectiveness of SGLT2 inhibitors and DPP4 inhibitors in patients with type 2 diabetes and cardiovascular disease, finding that SGLT2 inhibitors were associated with lower risks of major adverse cardiovascular events.
Interventions
SGLT2 inhibitors
Outcomes
All-cause mortalityComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)Heart failure hospitalizations+1 more
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the CamAPS FX algorithm with simplified meal announcement against carbohydrate counting in youth and young adults with type 1 diabetes, finding non-inferiority in glucose control.
Interventions
Low-carbohydrate dietVery-low-calorie ketogenic diet
Outcomes
Percentage of time spent above 10.0 mmol/LTime above 13.9 mmol/LTime in range+1 more
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of sitagliptin on carotid intima-media thickness in type 2 diabetes patients. It found no significant change in IMT but a notable reduction in HbA1c levels.
Outcomes
Common carotid artery intima-media thickness (IMT)Episodes of serious hypoglycemiaHbA1c
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the effects of sitagliptin plus metformin therapy on metabolic profiles in patients with type 2 diabetes and NAFLD, finding significant improvements in various metabolic markers.
Interventions
Dipeptidyl peptidase-4 inhibitorsMetformin
Outcomes
Alanine Aminotransferase (ALT)Fasting blood sugar (FBS)Glycemia risk index+2 more
Added to Dediabetes Jul 12, 2026RCTs
This study evaluated the impact of the DiaCert smartphone app on physical activity levels in adults with Type 2 diabetes. Results indicated no significant improvements in moderate to vigorous physical activity or other health metrics.
Interventions
Rama Diabetes Care app
Outcomes
BMIDiastolic blood pressureHDL cholesterol+7 more
Added to Dediabetes Jul 12, 2026RCTs
This study examined the effects of smartphone applications on oral hygiene and glycemic control in diabetic patients, finding significant improvements in HbA1c levels and oral health behaviors.
Interventions
Smartphone applications for oral hygiene and glycemic control
Outcomes
Dental Neglect Scale ScoreHbA1cQuality of life+2 more